Hims & Hers Health Inc. Aktie News

Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius Pharmaceuticals for Kyzatrex positions it to capture a larger share of the growing testosterone therapy market and cross-sell to existing users. Despite premium valuation multiples, HIMS maintains...

Hims stock is near a buy point of 60.55 in a cup-with-handle base. The IBD 50 growth stock has gained 126% year-to-date.

The market often gets worried when a company announces a major change in its C-suite. On news that it was doing just that, on Friday the stock of consumer healthcare company Hims & Hers (HIMS -9.05%) was whacked with a more than 9% sell-off by investors.

PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ --  Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its p...

Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.

Amazon's success expanding from books to cloud computing has set the benchmark for the ideal growth stock. By putting the customer first and being willing to take risks, Amazon tremendous wealth for investors.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.

Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuation reflects high growth expectations, leaving little room for missteps amid FDA scrutiny of compounded GLP-1 marketing and new tariff uncertainties. I'm expecting Hims & Hers to see near-term volati...